Actively Recruiting

Phase Not Applicable
Age: 25Years - 48Years
FEMALE
NCT07390864

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

Led by Cairo University · Updated on 2026-02-05

40

Participants Needed

1

Research Sites

32 weeks

Total Duration

On this page

Sponsors

C

Cairo University

Lead Sponsor

K

Kafrelsheikh University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids. The main questions it aims to answer are: Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy? Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy? Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop? Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes. Participants will: Undergo abdominal myomectomy for uterine fibroids Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

CONDITIONS

Official Title

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

Who Can Participate

Age: 25Years - 48Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female participants aged 25 to 48 years
  • Body mass index (BMI) less than 35 kg/m8
  • Symptomatic uterine fibroids needing surgical treatment
  • Uterine fibroids classified as FIGO types 3 to 6 by ultrasound or MRI
  • Largest fibroid diameter 20 cm or less
  • Scheduled for abdominal myomectomy
  • Able and willing to provide written informed consent
Not Eligible

You will not qualify if you...

  • Fibroids of FIGO types 0, 1, 2, 7, or 8 (intracavitary, submucosal, pedunculated subserosal, cervical, or adnexal)
  • History of pelvic inflammatory disease, peritonitis, or significant abdominal or pelvic infection
  • Prior uterine surgery
  • Hormonal treatment within 3 months before enrollment
  • Contraindications to methylergometrine or carbetocin (allergy, hypertension, cardiac or pulmonary disease, chronic endocrine or metabolic diseases like diabetes, renal or hepatic impairment)
  • High bleeding risk, including bleeding disorders or current use of antiplatelet or anticoagulant drugs
  • Preoperative anemia with hemoglobin below 10 g/dL
  • BMI 35 kg/m8 or higher
  • Conversion from myomectomy to hysterectomy during surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fayoum University

Al Fayyum, Faiyum Governorate, Egypt, 38521

Actively Recruiting

Loading map...

Research Team

A

Ahmed E Abd eltawab, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here